PhotoCure Pursues Niche Cancer Market In Wake Of Skin Lesion Approval
This article was originally published in The Gray Sheet
PhotoCure will target an additional 1 mil. cases per year in the U.S. with approval of a basal cell carcinoma indication for Metvix therapy, expected by year-end, the firm says
You may also be interested in...
PhotoCure's methyl aminolevulinate could be approved as part of a "niche" basal cell carcinoma phototherapy regimen for patients who are intolerant to other treatments, an FDA advisory committee said in voting against a broader indication
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.